InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.33
(
0.48%
)
Bitcoin
58,195.97
(
-3.27%
)
Post# of 252484
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: poorgradstudent post# 4116

Thursday, 10/14/2004 11:10:39 AM

Thursday, October 14, 2004 11:10:39 AM

Post# of 252484
>> I don't consider the Retaane trial to be a failure in the clinical sense. We have no idea whether or not the patients who respond to Retaane versus Visudyne are overlapping populations, or entirely exclusive populations <<

True, but the Retaane results are not impressive in an absolute sense. After one year, 55% of the Retaane patients had lost 3 or more lines of vision, and few (if any) patients experienced improved vision.

Retaane’s best chance for commercial success may in retarding the progression from dry AMD to wet AMD. Studies testing this are underway and results will be out in about six years.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up